The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Immune-related adverse effect/toxicity
Publications
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26(12):2375-91
Checkpoint blocking antibodies in cancer immunotherapy.
FEBS letters. 2014;588(2):368-76
Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.
Annals of the New York Academy of Sciences. 2010;1183:222-36